Immuneering

Immuneering is a clinical-stage oncology company that develops medicines for cancer patients. Its approach combines translational bioinformatics with computational biology and a deep understanding of cancer biology. Its lead candidate is atebimetinib (IMM-1-104), an oral once-daily deep cyclic inhibitor of MEK. It is being studied in pancreatic cancer and other RAS-driven tumors. Its mission is to deliver durable benefit to patients with hard-to-treat cancers.